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Summary
Small-molecule kinase inhibitors are predominantly
discovered in pure protein assays. We have discov-
ered an inhibitor of Rho-kinase (ROCK) through an
image-based, high-throughput screen of cell mono-
layer wound healing. Using automated microscopy,
we screened a library of 16,000 compounds finding
many that affected cell migration or cell morphology
as well as compounds that blocked mitotic pro-
gression. We tested 200 compounds in a series of
subassays and chose one, 3-(4-pyridyl)indole (Rock-
out), for more detailed characterization. Rockout in-
hibits blebbing and causes dissolution of actin stress
fibers, phenocopying Rho-kinase inhibitors. Testing
Rho-kinase activity in vitro, Rockout inhibits with an
IC50 of 25 M (5-fold less potent than Y-27632) but has
a similar specificity profile. We also profile the wound
healing assay with a library of compounds with
known bioactivities, revealing multiple pathways in-
volved in the biology.
Introduction
Cell migration requires the coordination of numerous
cellular processes including polarization, actin cyto-
skeletal reorganization, membrane cycling, and adhe-
sion. One approach to studying this complex phenome-
non has come through the use of small molecules
which can be used to temporally and spatially regulate
individual proteins and processes. Numerous small
molecules that are known to inhibit cell migration exist
and have been used extensively; however, our ability to
perturb specific protein function is limited by the com-
pounds available.
Small molecules that are commonly used to study
cell migration have predominantly been discovered
through their activity in non-cell migration assays (tox-
icity and proliferation), rather than by high-throughput
screening of the phenomenon itself [1–3]. In recent
years, technology development has allowed high-
throughput screens that assay cellular and multicellular
phenomena, and allow observation of complex pheno-
types. These include: G protein-coupled receptor shut-
tling, protein translocation through the ER and Golgi to
the plasma membrane, nuclear translocation, angio-*Correspondence: jyarrow@post.harvard.edugenesis, and progression through the cell cycle [4–6].
These screens are known as phenotypic screens and
in an analogy to genetic screens, they aim to discover
a small-molecule inhibitor for each protein involved in
a process [7]. Cell imaging provides an interesting read-
out of phenotypic screens. Image-based screens pro-
vide detailed information about the process under
study and as such are often referred to as high content
screens [8–10].
We developed an image-based, high content, cell mi-
gration screen in a 384-well format using scratch wound
healing as a model system [11]. Using this assay, we
screened for compounds that affect wound healing and
cell migration. In beginning this work, we had two goals:
finding small-molecule tools for in-depth cell biological
study and developing technologies for image-based
screening. We performed a large phenotypic screen for
migration-inhibiting small molecules then took the hits
through a series of more detailed assays and molecular
characterization. This resulted in the characterization of
a small molecule, the identification of its protein target,
and the development of a linked series of assays that
can be used in future screens of small-molecule, siRNA,
and protein libraries.
Results
Screening for Small Molecules that Affect
Wound Healing
We developed an assay for finding inhibitors or activa-
tors of cell migration using automated microscopy to
observe migration of mammalian epithelial cells 7 hr
after wounding of a confluent monolayer [11]. In this
type of migration assay, cells are thought to respond to
increased exposure to serum growth factors at the
wound margin by chemotaxis into the open area [12,
13]. We screened library of w16,000 drug-like small
molecules at a nominal concentration of 50 M, and
observed four predominant phenotypes: decreased
migration, aberrant morphology of migrating cells, in-
creased number of round cells (found for the most part
to be mitotic cells), and compounds that disrupted the
cell monolayer (Figure 1A). No activators of migration
were observed, presumably because the high serum
concentration in our assay maximally stimulated migra-
tion. Monolayer disruption was considered a gross indi-
cation of toxicity, and compounds with this effect were
typically not tested further. Wells often showed a com-
bination of phenotypes (e.g., both inhibition of wound
healing and aberrant morphology).
From the initial 16,000 compounds, w150 com-
pounds decreased migration, w600 compounds caused
aberrant morphology, andw450 compounds increased
the number of mitotic cells. The initial categorization
was intentionally broad, and compounds were placed
in multiple categories. Removing redundancy, as well
as compounds that increased the number of mitotic
cells, or caused complete disruption of the monolayer,
we were left with w400 compounds that affected mi-
gration or morphology.
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(A) The five predominant phenotypes observed in a primary screen for small molecules that affect 7 hr wound healing of BS-C-1 monolayers:
normal, decreased cell migration, aberrant cell morphology, increased mitotic cells, and disrupted monolayer (toxic). Cells are stained with
phalloidin to visualize filamentous actin.
(B) Compound structures from each of the 24 structural classes found to have an effect in the wound healing assay.To narrow the number of compounds for subsequent c
tstudy, we categorized compounds into 24 classes of
chemically related molecules by visual inspection of c
cstructures (Figure 1B), plus 278 singleton compounds.
From each structural class, we chose the compound c
twith the most drastic effect on cells for follow-up, as-
suming (possibly incorrectly as discussed below) that C
lother compounds in the same class act by the same
mechanism, but less potently. From the singletons, we f
cselected compounds on the basis of attractive chemi-
cal features, including: multiple heterocyclic rings, ni- p
otrogen containing heterocycles, polar groups, expectedhemical stability, and lack of chemically reactive func-
ionality [14]. The resulting sublibrary of w200 active
ompounds was screened in several other assays, and
ompared to a database of activities for the larger
hemical library. The assay that was most relevant to
he wound healing screen was an in vitro screen of
dc-42-dependent actin polymerization in Xenopus
aevis frog egg extract [15, 16]. This assay was per-
ormed prior to ours and targeted a subset of the pro-
esses involved in wound healing. We excluded com-
ounds found to inhibit in both this in vitro assay and
urs.
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number of mitotic cells from further analysis of cell mi-
gration effects, these compounds merit further com-
ment. Finding wells with an increased number of mi-
totic cells was an unexpected bonus in our screen,
reflecting the high information content of microscopy
images. These wells were restained with an anti-tubulin
antibody and inspected at higher magnification. One
compound gave a monoaster phenotype and was sub-
sequently shown to inhibit the mitotic kinesin Eg5 [17].
Visual inspection of the other mitotic wells showed
either microtubule depolymerization or a phenotype
characteristic of a microtubule dynamics perturbation
(a smaller mitotic spindle with chromosomes at the
poles and throughout the length of the spindle), and a
subset of these were confirmed as tubulin polymeriza-
tion inhibitors in vitro (T. Mayer, personal communica-
tion). However, some of the suspected microtubule de-
polymerizers score differently with respect to inhibiting
migration, suggesting that some compounds may target
other proteins involved in microtubule dynamics, or
target tubulin as well as another process.
Secondary Assays Define One Compound,
Rockout, for Follow-Up
With approximately 200 compounds in hand, we devel-
oped a series of secondary assays to narrow the
number of compounds further and to profile their bio-
logical activity. We were particularly interested in find-
ing compounds that affected proteins and processes
involved in the regulation of the actin cytoskeleton, but
we didn’t want to limit ourselves to these processes.
We therefore selected secondary assays that were sen-
sitive to small-molecule inhibitors of the actin cytoskel-
eton yet were significantly complex that inhibition of
other processes would manifest in the assays. Other
major considerations in choosing subassays were the
rapidity of the readout of an assay and developing a
set of assays that monitored overlapping and comple-
mentary processes (Table 1). Assays with rapid read-
outs were chosen to select compounds that affect the
dynamic aspects of an assay rather than those aspects
that took hours to manifest, e.g., changes in transcrip-
tion and translation. The range of assays—from com-
plex, in vivo, to simpler, in vitro, assays—was chosen
with the hope that some compounds would inhibit inTable 1. Characteristics of the Assay and Subassays
Minimum Duration Complexity of Underlying
Assay Assay Type Required for Readout Biology (Subjective Rank)
Wound healing Multi and single cell 7 hr 1
Phagocytosis Single cell w1 hr 2
M2 blebbing Single cell 10 min 3
Timelapse microscopy Single cell 10 min 3
Cell spreading after trypsinization Single cell w30 min 3
Toxicity Single cell 10 min 4
Actin polymerization in permeabilized In vitro 10 min 5
S. cerevisiae
Listeria-dependent actin polymerization In vitro 10 min 5
The characteristics described above define a set of assays with overlapping complexity, biochemical accessibility, and rapidity of readout
that can be used to subdivide compounds for follow-up. (The subjective ranking is based on the assay type and what is known from
observation or the literature.)both types of assays and thus select for compounds
that were potentially specific. The use of overlapping
assays would also narrow the number of potential
targets (from many in an in vivo assay to fewer in an in
vitro assay) and provide a route to target identification
via biochemical methods (Table 1). We used the follow-
ing assays: IgG mediated phagocytosis of E. coli by
macrophages, cell spreading, cell blebbing, observa-
tion of cellular effects by time-lapse microscopy, actin
polymerization in permeabilized S. cerevisiae, in vitro
Listeria monocytogenes motility, and toxicity measured
by membrane permeability and ATP levels (Figure 2A)
(see Experimental Procedures for details).
From our 200 active compounds, we found inhibitors
that were active in each subassay except Listeriamotil-
ity and actin polymerization in permeabilized yeast;
however, nearly all compounds showed undesirable ef-
fects, including: toxicity after 24 hr treatment (some
were toxic after 7 or 2 hr; data not shown), vacuoliza-
tion of cells when observed by transmitted-light mi-
croscopy, or insolubility at low concentrations.
One compound that was not toxic, promoted cell
spreading, and inhibited blebbing, was 3-(4-pyridyl)in-
dole (Rockout) (Figure 2B). Rockout initially scored as
a compound that caused decreased migration and ab-
errant morphology. A dose-response series shows a
distinct effect in the wound healing assay at 50 M (Fig-
ure 2C). Rockout did not affect phagocytosis, Listeria
motility or actin polymerization in permeabilized yeast.
Rockout Inhibits Blebbing and Leads
to Dissolution of Stress Fibers
Rockout was chosen for follow-up after observing that
treatment inhibited blebbing of recently trypsinized
Swiss3T3 cells (data not shown)—an effect that was
not observed with any of the other compounds tested
and was intriguing given what is known about the role
of the actin cytoskeleton in the phenomenon of bleb-
bing [18–21]. We observed the same effect when test-
ing Rockout on blebbing using M2 cells, a human mela-
noma cell line that blebs constitutively in a manner that
is sensitive to actin cytoskeletal perturbation [19–23].
When Rockout was added at 50 M, M2 cells stopped
blebbing within 2 min and with washout blebbing re-
turned to normal levels within 3 min (Figure 3A).
Monitoring blebbing of M2 cells is a robust, rapid as-
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(A) Three of the secondary assays used to narrow the compounds found in the wound healing screen—phagocytosis, cell spreading, and live
cell/dead cell. The phagocytosis assay shows a compound with normal phagocytosis, the effect of cytochalasin D, and a compound that
blocked phagocytosis but showed balled and brightly staining cells which suggest toxicity. The cell spreading assay found compounds that
had no effect on spreading, led to spreading with aberrant morphology, allowed adherence but not spreading, and led to fewer cells adhering.
A live cell/dead cell assay 24 hr after wounding. DMSO treatment shows complete healing after 24 hr (live cells stained with calcienAM) and
minimal dead cells (ethidium homodimer staining is minimal). A compound that blocks wound healing after 24 hr shows increased toxicity.
(B) The structure of Rockout, 3-(4-pyridyl)indole, chosen for follow-up studies after performing subassays.
(C) Titration of Rockout in the wound healing assay shows that it has a distinct effect on morphology at 50 M.say that allowed us to quantify the effect of Rockout d
gand its derivatives. Inhibition of blebbing by Rockout
can be easily seen after fixation and staining for fila- t
omentous actin (Figure 3B). To determine an IC50 for
Rockout, we treated cells for 10 min with a dilution m
oseries before staining and counting cells with blebs. We
found that Rockout has an IC50 of w12 M (Figure 3B) r
dand it inhibits blebbing in nearly all cells at 50 M—
the concentration used for subsequent experiments. To a
wbegin to establish a structure-activity relationship, we
tested two derivatives of Rockout and a control com- p
ipound with similar chemical characteristics. We found
that RD2 had a dose response similar to Rockout, RD3 n
(had almost no effect at up to 100 M, and RD4 also
had no effect (Figure 3B). RD3 and RD4 had no effect a
aon longer incubation in time-lapse microscopy experi-
ments (data not shown). These structure-activity studies m
reveal the importance of one of the heterocyclic nitro-
gens, and point to a site for future chemical modifica- R
Gtion to increase potency.
Balb 3T3 (B3T3) cells, a fibroblast cell line, have wellefined actin structures, and we used them to investi-
ate the specific effect of Rockout on the actin cy-
oskeleton. Treatment of B3T3 cells with 50 M Rock-
ut leads to significant morphological change within 10
in in a manner that suggests changes in contractility
r adhesion (Figure 3C). Cells do however continue to
uffle, suggesting leading edge activity (which is depen-
ent on rapid actin polymerization) is normal. We fixed
nd stained cells for filamentous actin after treating
ith 50 M Rockout for 10 min. Cells treated in the
resence of serum showed decreased stress fiber stain-
ng, and this effect was more easily observed after over-
ight serum starvation followed by Rockout treatment
Figure 3D). Localization of the stress fiber and focal
dhesion complex proteins α-actinin, filamin, vinculin,
nd ezrin, were also disrupted by the Rockout treat-
ent (data not shown).
OCK Is a Molecular Target of Rockout
iven the effect of Rockout on cell morphology, stressfibers, and blebbing, we suspected that it might be act-
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389Figure 3. Rockout Inhibits Blebbing in M2 Cells and Leads to Stress Fiber Disassembly
(A) Constitutively blebbing M2 cells stop blebbing within 2 min after the addition of 50 M Rockout and return to normal levels within 3 min
after washout. Arrows note prominent blebs.
(B) High magnification images of the phenotypes used in quantifying the effect of Rockout and derivatives below. Fixed and stained for
filamentous actin after 2 min, cells show blebs in DMSO and do not in 50 M Rockout.
(C) A Rockout dilution series (100, 50, 25, 12.5, and 6 M) shows that Rockout blocks blebbing in all cells at 50 M and has an approximate
IC50 of 12 M. RD1 inhibits blebbing with a similar IC50 while RD3 and RD4 have little or no effect. M2 cells were treated with a dilution series
of the compounds noted for 10 min, fixed, stained, and counted.
(D) Balb 3T3 cells treated with 50 M Rockout show effects within 10 min that are consistent with perturbation to contractility or adhesion.
Arrows note ruffling protrusions following contraction.
(E) Serum-starved cells treated with 50 M Rockout for 10 min show loss of stress fibers compared to DMSO treatment.ing in the Rho pathway. Treatment with Y-27632, a small-
molecule inhibitor of Rho kinases (ROCKI and ROCKII,
hereafter ROCK), leads to stress fiber dissolution, af-
fects cell morphology, and inhibits blebbing [20, 24–27].
We found that the effect of 50 M Rockout was equiva-
lent to that of 10 M Y-27632 on stress fiber dissolution,
and subsequent experiments used these concentra-
tions, respectively (data not shown). We directly investi-
gated the effect of Rockout on the Rho signaling path-
way, using myosin light chain (MLC) phosphorylation
as a readout. Rho-kinases are serine/threonine kinasesthat are activated by Rho [28]. Upon activation of the
Rho pathway, ROCK interacts with and phosphorylates
downstream effector proteins, including myosin light
chain [29–31]. To test for an effect on MLC phosphory-
lation, we starved M2 and B3T3 cells overnight, incu-
bated with compounds for 10 min, stimulated with se-
rum or not, and harvested after 10 additional minutes.
Using an antibody specific to phosphorylation of MLC
at Ser19, we found that, in both the presence and ab-
sence of serum, Rockout and Y-27632 caused a similar
decrease in phosphorylation levels (Figure 4A). To de-
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Similar to Y-27632
(A) Rockout and Y-27632 block myosin light
chain phosphorylation in Balb 3T3 cells and
M2 cells but do not block Rho activation. Re-
presentative Western blots of cell lysates af-
ter treatment with DMSO, 50 M Rockout
(RO), or 10 M Y-27632 with or without se-
rum stimulation.
(B) MLCK in vitro activity is not inhibited by
Rockout at concentrations up to 100 M but
is inhibited by the MLCK inhibitor ML-7 or by
the absence of calmodulin (CaM) in the
assay.
(C) Rockout inhibits ROCK in vitro activity at
50 M in a manner similar to 10 M Y-27632.
(D) Titration of Rockout and Y-27632 shows
an approximate IC50 of 25 M for Rockout
and 5 M for Y-27632 as measured in this
assay.termine where in the Rho pathway Rockout acts, we p
htreated B3T3 cells as above, and assayed Rho activa-
tion by a pull-down assay with immobilized Rho binding n
ldomain (RBD) from Rhotekin [32]. Rockout did not in-
hibit Rho activation (Figure 4A), showing that it acts be- P
nlow Rho in the pathway.
Myosin light chain is primarily phosphorylated by P
wboth myosin light chain kinase (MLCK) and ROCK. To
test the effect of Rockout on MLCK activity, we per- t
iformed in vitro kinase assays using human platelet my-
osin as substrate. Rockout did not affect phosphoryla- H
tion by MLCK (up to 100 M) while the MLCK inhibitor
ML-7 blocked phosphorylation at 50 M (Figure 4B). P
We next tested directly if Rockout inhibits ROCK ac- C
tivity. Performing kinase assays with purified ROCK W
catalytic domain [29] and myelin basic protein as sub- t
strate, we found that 50 M Rockout inhibits ROCK in s
a manner similar to 10 M Y-27632 (Figure 4C). A dose b
response of Rockout and Y-27632 showed an approxi- a
mate IC50 of 25 M for Rockout and 5 M for Y-27632 a
at an ATP concentration of 100 M (Figure 4D). Y-27632 S
is a competitive inhibitor, competing with ATP [33], and m
preliminary experiments with Rockout show that it is k
also competitive with ATP (data not shown). c
t
Rockout Kinase Specificity
Small-molecule inhibitors often have multiple targets, k
wand this is especially likely to be true for ATP-competi-
tive kinase inhibitors, given the conserved nature of ki- f
tnase active sites. Our pathway analysis already demon-
strated that Rockout is not a nonspecific kinase c
iinhibitor. Phosphorylation of AKT and ERM proteins
and phosphotyrosine levels in response to serum addi- c
ption were also unaffected (Figure 5A). To test Rockout’s
specificity we assayed its effect on five other kinases p
pin vitro. Using a concentration of 25 M (our measured
in vitro IC50), we tested kinases that have been shown r
tto be inhibited by Y-27632, and other ROCK inhibitors,
as well as kinases that are not inhibited by these com- pounds [34]. As seen in Figure 5B, 25 M Rockout in-
ibits ROCK-II and PRK2, another Rho-dependent ki-
ase, to a similar degree, and MSK-1 and PKA to a
esser extent (Figure 5B). Rockout does not inhibit
KCα or SAPK2a. In a profiling study of numerous ki-
ase inhibitors, the compound H-89 inhibited ROCKII,
KA, S6K1, and MSK1 with similar potency [34]. Thus,
e have found a ROCK inhibitor with 5-fold lower po-
ency than Y-27632 when tested in vitro and a specific-
ty profile that is most similar to the ROCK inhibitor
-89.
rofiling the Wound Healing Assay Using
ompounds with Known Bioactivities
e were also interested in determining the possible
argets of the other compounds discovered from our
creen. Compounds with established bioactivities can
e used in this respect to determine how a biological
ssay responds to a wide array of known perturbations
nd in this way reveal potential small-molecule targets.
uch compounds come with caveats; they might have
ultiple targets and some of those targets might not be
nown. However, small molecules with known activities
an focus attention on particular pathways, including
hose that would not otherwise be considered.
We screened a library of w500 compounds with
nown bioactivities at three concentrations in the 7 hr
ound healing assay. These compounds were selected
rom commercial sources to cover a wide range of
argets and processes and similar collections are now
ommercially available (for a complete list, see the link
n Experimental Procedures). After screening in dupli-
ate, wells that differed significantly from the control
henotype were categorized by visual inspection, as
er our original screen. We then assigned each com-
ound a number from 1 to 3 (highest to lowest) that
eflected the strength of the phenotype. Compounds
hat were toxic at the lowest concentration and com-
ounds that clearly increased the number of mitotic
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Other ROCK Inhibitors
(A) Rockout has no effect on pAKT, pERM,
or pTyr levels. Representative Western blots
of cell lysates after treatment with DMSO, 50
M Rockout (RO), or 10 M Y-27632 with or
without serum stimulation.
(B) Testing other kinases with 25 M Rock-
out in vitro, we find that Rockout has a spec-
ificity profile similar to the ROCK inhibitor
H-89, inhibiting ROCKII, MSK1, and PKA.cells were automatically ranked 3. Though subjective,
visual inspection reveals compounds and phenotypes
that do not fit the parameters of a defined automated
analysis and as such is more inclusive [11]. Out of 489
compounds, we found 37 that consistently affected mi-
gration (Figure 6A) and 12 that primarily affected mor-
phology (Figure 6B). A complete dataset, including
images, is available upon request. of action of all 489 compounds. We then categorized
Figure 6. Compounds with Known Bioactivities that Affect Migration and Morphology in the Wound Healing Assay
(A) Compounds that predominantly affect cell migration.
(B) Compounds that affected cell morphology but not migration.
For both, the column designations that are not self-explanatory are: Strength, the severity of the compound’s effect on a decreasing scale
from 1 to 3 (only 1 and 2 are shown); Conc., the concentration, high, medium, or low, at which a phenotype was observed; Target Cat.,
classification of the targets of the small molecules.Profiling with known bioactives, we found many ex-
pected compounds, such as the actin disrupting drugs
cytochalasin D, jasplakinolide, and latrunculin B. Oth-
ers were less expected, such as the CDK inhibitor al-
sterpaullone and the kinase inhibitor rottlerin (Figure 6).
To determine how the compounds might be affecting
wound healing, we compiled the published mechanism
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oand show the highest (most encompassing) level of
iclassification. These are defined as homeostasis, sig-
hnaling, cytoskeleton, and cell cycle. As expected with
ca broad phenotypic screen, compounds that affect core
ocell physiology, such as ion homeostasis and mem-
ibrane integrity, were found to inhibit in the assay. Inter-
oestingly, there were a significant number of compounds
athat affect the actin cytoskeleton and compounds that
starget specific signaling cascades suggesting that the
rproteins and pathways listed in Figure 6 are targets of




bWe have used a broad phenotypic screen to character-
size a small molecule, Rockout, found one of its protein
btargets, ROCK, and developed a series of subassays
tfor the discovery of small molecules that affect the ac-
ttin cytoskeleton. Beginning with a high-content image-
ibased screen of scratch wound healing, we found a
enumber of small molecules that decreased cell migra-
mtion, affected cell morphology of migrating cells, or in-
mcreased the number of mitotic cells. We categorized
cthese compounds based on chemical characteristics
pand chose a subset for screening in subassays of spe-
tcific and general aspects of cell physiology. From these
osubassays, we chose one compound, Rockout, for fol-
slow-up studies. Rockout blocks blebbing in M2 cells
tand decreases stress fibers in Balb 3T3 cells. Biochem-
fically, Rockout decreases myosin light chain phosphor-
oylation levels, an effect that is also seen with the ROCK
inhibitor Y-27632. Testing the predominant kinases that
mphosphorylate myosin light chain, we found that Rock-
sout does not affect myosin light chain kinase (MLCK)
T
activity but does directly inhibit ROCK.
m
Our most concrete achievement in this work was to
g
identify a potentially useful inhibitor-protein pair, Rock-
s
out-ROCK. Kinases are among the most important c
targets for therapeutic drug discovery, and the normal t
route to finding them is pure protein screening. Our t
data illustrates that phenotypic screening can also be p
used to discover kinase inhibitors, and in general we s
believe automated microscopy will be a useful tool for e
phenotypic characterization in kinase drug discovery c
programs. Further experiments will be required to ex- v
plore Rockout’s utility as a reagent. Rockout is less po- t
tent than the existing ROCK inhibitors Y-27632, H89, b
and HA1077, but its specificity appears to be compara- f
ble. Rockout is a low molecular weight (194.2) and hy- i
drophilic (logP calc = 2.5 ± 0.3) compound making it s
“lead-like” in its physical properties [35, 36]. These are p
reasonably impressive characteristics for a compound t
straight out of a screen, and our structure-activity data a
show that Rockout can be modified without losing ac- u
tivity, suggesting that more potent derivatives could be t
synthesized. Human ROCKs are considered potential h
targets for therapeutic drug development, for example w
in vascular disease [37, 38], so a heterocyclic scaffold b
for ROCK inhibitors is potentially useful. f
Rockout was only one of many bioactive compounds b
we identified, because our phenotypic screen covered d
a broad range of target proteins and processes. An un-xpected bonus was identification of useful inhibitors
f cell division [17], demonstrating the utility of the high
nformation content inherent in cell imaging. The wound
ealing assay could be made more specific for finding
ompounds involved in cell migration by modification
f the screen itself, or by use of baseline assays to elim-
nate compounds that have global effects on cell physi-
logy. For example, the screen could be converted into
differential screen, by comparing wound-migration re-
ponses to different trophic factors, or by comparing
esponses of different cell types to the same trophic
actor. It could also be converted into a screen of mi-
ration enhancers by using suboptimal concentrations
f trophic factors or serum. As an alternative, undesir-
ble compounds could be eliminated from further study
y extensive baseline assays. Our use of toxicity as-
ays proved to be highly informative; a number of other
aseline assays, such as assays for transcription/
ranslation inhibitors, might similarly be employed in fu-
ure screens. The results of the screen were also greatly
nfluenced by the initial criteria used for defining inter-
sting hits. The assumption that the compound with the
ost drastic effect within a structural class was the
ost potent compound of that class was probably in-
orrect as we and others have found that these com-
ounds have a very sharp transition from toxic effects
o no effect (T. Mayer, personal communication). An-
ther criterion used was toxicity after 24 hr. In retro-
pect, this is too stringent a criterion for compounds
hat will be used as tools for cell biological study. Ef-
ects observed at 24 hr are not necessarily indicative
f, or relevant for, use in a 1 hr or 10 min assay.
As a side benefit of this work, the complexity of cell
igration necessitated the development of a number of
econdary assays for specific actin-based processes.
hese assays are not a definitive roadmap for small-
olecule discovery of compounds that affect cell mi-
ration—they conspicuously ignore aspects of adhe-
ion and do not actively test different signaling cas-
ades—but they do suggest general characteristics for
he development of a set of assays that can be used
o narrow and profile compounds found from a broad
henotypic screen. Many of these assays can them-
elves be adapted for high-throughput screening. For
xample, both the phagocytosis and blebbing assays
an easily be performed in multi-well format and, as
ery dynamic processes, allow readouts in a short
ime—1 hr and 10 min, respectively. Phagocytosis and
lebbing are good assays in part because they mani-
est the behavior of the highly plastic actin cytoskeleton
n discrete and definable ways. And though these as-
ays are susceptible to compounds with global effects,
hagocytosis can be monitored throughout the process
o determine which step is inhibited (reviewed in [39])
nd the process of blebbing consists of discrete molec-
lar events that define bleb formation, size, and retrac-
ion (G.T.C., unpublished result). In fact, phagocytosis
as been used in a medium throughput format [40] and
e have used blebbing as an assay for screening a li-
rary of compounds with known bioactivity and have
ound numerous compounds that had not previously
een known to inhibit blebbing (G.T.C., unpublished
ata).
With the completion of this phenotypic screen, we
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can contribute to the discovery of small molecules.
They can be used, as here, to capture the broad array
of biological processes that feed into and affect a given
process. They can also be tailored to answer narrowly
defined and specific questions; for example, by screen-
ing for differential effects we might gain insight into dif-
ferences between cell types that migrate collectively as
sheets rather than as individual cells. In both cases,
there is a balance between the breadth of potential
targets and one’s ability to determine the specific target
of a given small molecule. To help better define the uti-
lity of a phenotypic screen and the compounds discov-
ered with it, initial profiling of an assay with a broad set
of small molecules with known bioactivities can provide
a sense for the biological processes that could be
targets within the screen. Then, once hits have been
found, the use of baseline and secondary screens can
decrease the number of compounds that inhibit the as-
say via undesired pathways while subdividing com-
pounds for follow-up.
Significance
We have demonstrated that an image-based screen of
a broad biological problem can be used, with appro-
priate follow-up, to discover interesting ligand-target
protein pairs that are relevant to both basic cell biol-
ogy and therapeutic drug discovery. In the future it
will be important to find more small molecules that
specifically target proteins involved in cell migration,
and variants of the screen and subassays we de-
scribe should be useful for this.
Experimental Procedures
Tissue Culture
BS-C-1, Balb 3T3, and J774A.1 cells (ATCC: CCL-26, CCL-163, TIB-
67) were grown in DMEM, 4.5 g/l glucose, 10% FCS, with antibiot-
ics. M2 cells were grown in MEM with Earl’s salts, 8% calf serum,
2% FBS, 10 mM HEPES (pH 7.5), and antibiotics. All cell lines were
maintained at 37°C, 5% CO2.
Screening of Compound Libraries
As described [11], 384-well clear-bottom plates were seeded with
BS-C-1 cells at a concentration of 8500 cells/well in 30 l of media
and incubated overnight. Compound library plates (Chembridge Di-
verSet E) were thawed and individual assay plates were wounded
immediately (within 3 min) with a 96-well pin-transfer device before
transfer of compounds. Pin transfer of compounds was accom-
plished using a robot (Seiko D-TRAN XM3106-31 PN 4-axis carte-
sian robot) with a 384 pin transfer (transfer volume of 100 nl) (VP
Scientific and http://iccb.med.harvard.edu/screening/technology_
screen_facil/pin_array_technology.htm). Based on the average mo-
lecular weight, compounds were screened at an approximate con-
centration of 50 M. Plates were incubated for 7 hr before fixing
and staining.
Fixation and Imaging of Screening Plates
Media was removed and permeabilization/fixation (perm/fix) solu-
tion (100 mM K-Pipes [pH 6.8], 10 mM EGTA, 1 mM MgCl2, 0.2%
Triton X-100, and 3.7% formaldehyde) was added as 30 l and in-
cubated for 15 min. Wells were aspirated, washed 2 times with TBS
containing 0.1% Triton-X 100 (TBS-Tx), and stained with 15 l TBS-
Tx containing 0.5 g/ml TRITC-phalloidin (Sigma P1591) and 0.1
g/ml Hoechst (Sigma B2261) for 15 min. Wells were washed 2
times with TBS-Tx and imaged. All liquid handling was done with awand aspirator (VP scientific VP-186L) and a Labsystems Mul-
tidrop.
Imaging and Visual Inspection of Compound Effects
Described in detail in [11]. In brief, individual wells were imaged
at 4× using an automated microscope. Images were captured and
compiled for visual inspection. Visual analysis of 1 plate of images
(384) took 10 min.
Phagocytosis
J774A.1 cells were seeded in 384-well clear bottom plates (as
above) at a density of 12,000 cells/well in 45 l of media and incu-
bated overnight. Compounds were pin transferred or added in 5 l
of media, briefly spun in a tabletop centrifuge (Sorval RT7 plus)
for 30 s at 500 rpm, and incubated for 30 min. Fluorescent E. coli
(Molecular Probes V-6694) were diluted as per instruction in Hank’s
balanced buffer salt solution. 0.5 l of diluted E.coli, were added
to each well in 5 l of media. Plates were spun for 5 min at 1500
rpm in a tabletop centrifuge (a critical step for consistent results)
and incubated for 1 hr. Media were removed and replaced with
bromophenol blue (Gibco 15250-061). Fluorescence was measured
using a plate reader (Wallac Victor2) and plates were visually in-
spected on an inverted microscope before images were taken with
the automated microscope with FITC and Rhodamine channels to
measure phagocytosis and toxicity (via cell permeability) respec-
tively. Wells showing a decrease of fluorescence levels of 33% rela-
tive to the control were noted, as were compounds that caused a
noticeable decrease in FITC fluorescence when observed by eye
or an increase in the percentage of cells that were fluorescent in
the Rhodamine channel.
Cell Spreading
Trypsinized Swiss 3T3 or BS-C-1 cells were added as 4500 cells in
50 l to a 96-well plate. Fifty microliters of media containing 1 l
of compound or DMSO was added to the wells and the plates were
spun in a tabletop centrifuge at 500 rpm for 30 s then incubated
for 50 or 75 min. Plates were analyzed by visually inspecting wells
and noting phenotypes prior to fixation as well as after fixation and
staining (fixed by adding 100 l of perm/fix solution containing 8%
formaldehyde and stained for actin and DNA as above). Com-
pounds that increased or decreased spreading as compared to
DMSO were noted, as were compounds that affected the morphol-
ogy of unspread or spread cells.
Permeabilized Yeast Actin Assembly
Permeabilized yeast actin assembly reactions were performed as
described [41, 42] with the modification that permeabilized cells
were not urea inactivated. Compounds, tested at 50 M, were
added with extract to the permeabilized cells and again during ac-
tin polymerization. The percentage of cells incorporating labeled
actin was noted—no compound treatment decreased actin incor-
poration below the control value of 50%.
Listeria-Dependent Actin Polymerization
Listeria reactions were tried in multiple formats including tail forma-
tion in total bovine brain extract and in a two-component system
both described in [43]. All compounds tested showed normal tail
formation as compared to DMSO except one compound that
blocked tail formation but allowed cloud formation. This compound
was inconsistent and was dropped from further study.
Time-Lapse Microscopy
Cells were seeded on 25 mm coverslips and adhered for 2 or more
hours before imaging. Coverslips were placed in an open-faced
chamber warmed to 37°C with 2 mls of media. Cells were treated
by removing half of the media from the chamber, mixing it with the
compound in an Eppendorf tube, and returning the media to the
chamber. Washouts were performed by at least 3× replacement of
existing media. With pretreatment and washout, DMSO concentra-
tion was kept constant. A compound that showed any effect to
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iruffling, rounding, or morphological changes—was noted.
a
CToxicity
bCell Titer ATP Assay (Promega G7571)
PBS-C-1 cells were plated in 384-well clear-bottom plates overnight
at a density of 2000 cells/well in 25 l. One microliter of compound
was added in 25 l of media to the wells and mixed. At time points R
of 2 hr and 7 hr, 50 l of cell titer solution was added. Plates were R
measured on a plate reader (Wallac) after 2 min of shaking and 8 m
min incubation. Compounds that showed a 20% decrease in fluo- f
rescence relative to the control were noted as toxic. R
Live Cell/Dead Cell Assay (Molecular Probes L7010) M
BS-C-1 cells were plated in 384-well clear bottom plates overnight m
as above for wound healing assays. Compounds were added in S
5 l of media to 45 l and incubated for 2 hr, 7 hr, or 24 hr with or G
without wounding. Ethidium homodimer and calcienAM were
added in 5 l for a final concentration of 20 M and 10 M, respec- K
tively. Plates were incubated 15 min and visualized by eye or im- R
aged using the automated microscope. Compounds that showed r
an increase in the percentage of cells stained with ethidium bro- H
mide were noted as toxic. b
B
Immunofluorescence 
Cells were fixed as described for screening plates above. Cover- i
slips were blocked in TBS-Tx containing 2% BSA (AbDil) for 30 min; r
antibodies diluted in AbDil were incubated for 45 min, washed 3
times with TBS-Tx, incubated for 45 min with secondary antibodies Sin AbDil, washed 3 times with TBS-Tx, 1 time with water; and
Cmounted in mounting media (0.5% p-phenylenediamine in 20 mM
sTris [pH 8.8], 90% glycerol). Antibodies and stains used: filaman
c(Oncogene Research Products CP72), α-actinin (Sigma A5044), ez-
brin (Sigma E8897), vinculin (Sigma V9131).
h
c
M2 Cell Blebbing Assay c
M2 cells were split into 12-well plates containing 10 mm coverslips. 1
After 2 hr, compounds were added to wells for 2 or 10 min. Cells d
were fixed for 10 min with the addition of an equivalent volume of i
media containing 8% formaldehyde. Cells were washed with TBS- a
Tx, stained with 0.5 g/ml TMR NHS-ester (Molecular Probes t
C-1171) for 10 min, washed with TBS-Tx, incubated with 1 g/ml
Hoechst for 2 min (found to be necessary for uniform NHS-ester
staining, possibly by quenching any remaining NHS-ester), washed
A2 times with TBS-Tx, and mounted.
WCell Signaling by Western Blotting
hM2 and Balb3T3 cells were plated in 6-well plates at 80% conflu-
lency. Cells were starved overnight in their respective media with
T0.1% FBS. Compounds were added to wells and incubated for 10
Smin before the addition of 10%–20% FBS in experiments involving
astimulation. After an additional 10 min, media was removed and
p300 l of Laemmli sample buffer was added. Samples were boiled
wfor 2 min, and sonicated before loading on SDS PAGE gels. Stan-
Tdard Western blotting techniques were used. Antibodies used:
fphospho-myosin light chain 2 Ser19 (Cell Signaling 3671), phos-
wpho-Akt Ser473 (Cell Signaling 9271), GAPDH (US Biological
bG8140-01), 4G10 (Upstate 16-204), and phospho-ERM (Cell Signal-
Ging 3141).
Activated Rho Pull-Down Assays R
Balb3T3 cells were plated, starved, and treated with compounds R
as above. After 5 min in the presence or absence of 20% serum, A
media was replaced by 300 l of 1× PBD (50 mM Tris-HCl [pH 7.5], P
10 mM MgCl2, 200 mM NaCl, 1% IGEPAL, and 5% glycerol), cells
were scrape collected and Rhotekin RBD pull-down assays were R
performed as described [32]. Immunoprecipitate was separated by
electrophoresis (12% SDS-PAGE) and blots were probed with RhoA
antibody (Santa Cruz sc-418).
MLCK Kinase Assay
Myosin light chain kinase activity was assayed in MLCK buffer (50
mM Tris [pH 7.0], 100 mM KCl, 10 mM MgCl2, 0.2 mM CaCl2, and
1 mM DTT). Each reaction contained 1 g human platelet myosin,.125 g calmodulin, and 38 ng MLCK. Reactions were mixed with
ndicated concentrations of inhibitor, then ATP was added to give
final concentration of 30 M cold ATP and 1.5 M g-32P-ATP (10
i/mmol). Reactions were incubated for 10 min at 30°C, stopped
y the addition Laemmli sample buffer, and separated by SDS-
AGE (15%).
OCK Kinase Assay
OCK activity was assayed with purified GST-ROCK catalytic do-
ain kindly provided by K. Kaibuchi [29]. Kinase assays were per-
ormed at 30°C for 20 min (unless otherwise noted) with 150 ng of
OCK in 30 l of buffer (20 mM Tris [pH 7.5], 50 mM NaCl, 5 mM
gCl2, and 1 mM DTT) with 0.1 mM ATP, 0.1 M g-32P-ATP (0.1
Ci/ml), and 3 g myelin basic protein. Samples were run on 15%
DS-PAGE gels, dried, and exposed to a phosphorimager screen.
el bands were quantified with Quantity One software (BioRad).
inase Specificity
OCK-II(h), PRK2(h), MSK1(h), and PKA(h) were chosen based on
esults that all or some are inhibited by the ROCK inhibitors Y-27632,
89, and HA1077 while PKC(α)(h), and SAPK2a(h) do not show inhi-
ition by these compounds [34]. A Kinase Profiler assay (Upstate
iotechnology) was performed in duplicate with 25 M FKAF, 100
M ATP, and assay conditions detailed at (http://www.upstate.com/
mg/pdf/kp_protocols_full.pdf). Data is plotted as average and
ange/O2.
creening of Compounds with Known Bioactivities
ompound plates (ICCB Bioactives 1, http://iccb.med.harvard.edu/
creening/compound_libraries/bioactives_collection1.htm) for each
oncentration were assembled from dry and liquid stocks by mem-
ers of the ICCB screening room. Three concentrations were made:
igh, 5 mg/ml; medium, 1.1 mg/ml; and low, 0.25 mg/ml with ex-
eptions made to accommodate extremely potent or nonpotent
ompounds. BS-C-1 were plated in 40 l after we pin transferred
00 nl from each compound plate. Compounds were screened in
uplicate in the 7 hr wound healing assay and fixed, stained, and
maged as before. The complete data set including images is avail-
ble upon request. Bioactivities were compiled from Pubmed cita-
ions, as well as Calbiochem, BioMol, and Tocris catalogs.
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